Pharmaceutical and Medical Device Regulatory Strategy in Poland

Introduction

Entering Poland can provide medical device manufacturers with access to a significant EU healthcare market. But market entry is not simply a matter of obtaining CE marking and beginning commercial activities.

Manufacturers must understand how the EU regulatory framework interacts with Polish requirements, economic-operator responsibilities, post-market surveillance, vigilance, documentation, language considerations, and evolving regulatory expectations.

For companies entering Poland for the first time, the most effective approach is to develop a regulatory strategy before commercial launch rather than treating compliance as a series of isolated submissions.

The same principle applies to pharmaceutical companies. Although medicinal products and medical devices operate under different regulatory frameworks, both require careful planning around authorization, lifecycle compliance, safety monitoring, documentation, and regulatory intelligence.

Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) is the national authority responsible for important regulatory functions involving medicinal products and medical devices.

For medical device manufacturers, therefore, a Poland market-entry strategy should begin with one question:

What regulatory pathway, documentation, local responsibilities, and post-market obligations will apply to the specific device and business model?

Why Regulatory Strategy Matters for Medical Device Market Entry in Poland

A regulatory strategy is more than a compliance checklist. It connects product classification, conformity assessment, quality systems, technical documentation, economic operators, market access, and post-market obligations.

For manufacturers entering Poland, early regulatory planning can help identify potential issues before they become expensive delays.

A regulatory strategy should answer questions such as:

• Is the product a medical device under the applicable EU legislation?
• Which classification rules apply?
• Is a notified body involved?
• Does the existing conformity assessment support the intended market?
• Are technical and clinical documents adequate?
• Are labeling and instructions for use appropriate for the Polish market?
• Which economic operators have responsibilities?
• What post-market surveillance activities are required?
• What vigilance procedures should be established?
• How will regulatory changes be monitored?

The European Commission identifies Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR) as the core EU frameworks governing medical devices and in vitro diagnostic medical devices.

This makes regulatory strategy particularly important for companies entering Poland from outside the European Union.

Understanding the Polish and EU Regulatory Framework

Poland operates within the broader EU regulatory environment. Consequently, companies should distinguish between EU-level requirements and Poland-specific implementation and operational requirements.

Medical Devices: MDR and IVDR

For medical devices, Regulation (EU) 2017/745 establishes requirements covering areas including:

• Device classification
• Conformity assessment
• Clinical evaluation
• Technical documentation
• Post-market surveillance
• Vigilance
• Economic operators
• Unique Device Identification
• Registration and information requirements

The European Commission also notes that the MDR and IVDR assign specific responsibilities to economic operators, making the roles of manufacturers, authorised representatives, importers, and distributors important parts of market-entry planning.

For companies headquartered outside the EU, understanding these responsibilities before entering the Polish market is particularly important.

Pharmaceutical Products

Medicinal products follow a different regulatory pathway.

The EU pharmaceutical framework requires medicinal products to obtain marketing authorization before being placed on the market, with authorization possible through centralized, national, mutual-recognition, or decentralized procedures depending on the product and circumstances.

The centralized procedure can provide a single EU marketing authorization for eligible medicines following scientific assessment by the European Medicines Agency and authorization by the European Commission.

For Poland-specific pharmaceutical activities, companies also need to understand the role of URPL and applicable national procedures.

This distinction is critical: medical device market entry in Poland should not be approached using a pharmaceutical regulatory model, and pharmaceutical registration should not be treated as equivalent to device conformity assessment.

Key Regulatory Steps for Medical Devices in Poland

A practical market-entry strategy can be divided into several stages.

1. Confirm Product Qualification and Classification

Before preparing submissions or commercial plans, determine whether the product falls within the scope of the MDR or IVDR.

Classification can affect:

• Conformity assessment route
• Notified body involvement
• Clinical evidence requirements
• Technical documentation
• Post-market obligations
• Regulatory timelines

A classification mistake made early can affect the entire market-entry strategy.

2. Assess Existing EU Compliance

Companies with an existing EU regulatory package should conduct a gap assessment rather than assuming that existing documentation automatically resolves every Poland-specific requirement.

Review:

• CE marking status
• Declaration of Conformity
• Technical documentation
• Clinical evaluation
• Risk management
• PMS documentation
• Vigilance procedures
• Labeling
• Instructions for use
• Economic-operator arrangements

Where a company is developing its regulatory pathway from the beginning, Medical Device Regulatory Strategy Services can serve as a useful reference point for understanding how product-specific regulatory planning fits into the broader market-entry process.

3. Review Economic-Operator Responsibilities

Manufacturers outside the EU generally need to consider the role of an EU authorised representative and understand the obligations of importers and distributors.

These responsibilities should be documented clearly.

A company should know:

• Who represents the manufacturer where required?
• Who imports the device?
• Who distributes it?
• Who maintains relevant records?
• Who communicates regulatory or safety information?
• Who supports corrective actions?
• Who coordinates with competent authorities?

Ambiguity between these roles can create avoidable compliance risks.

4. Review Language and Labeling Requirements

Language is a practical market-access consideration.

Technical documentation, labeling, instructions for use, promotional claims, and other product information should be reviewed against the requirements applicable to the product and intended use.

Translation should not be treated merely as a marketing exercise. Regulatory meaning, warnings, instructions, symbols, and safety information must remain accurate.

5. Prepare for Post-Market Obligations

Regulatory compliance does not end after market entry.

Manufacturers must establish appropriate processes for:

• Post-market surveillance
• Complaint handling
• Vigilance
• Trend reporting
• Corrective actions
• Field safety corrective actions
• Periodic documentation updates
• Regulatory reporting

This is why market-entry planning should connect pre-market and post-market regulatory activities.

The Role of Quality Management Systems

A strong Quality Management System (QMS) provides the operational foundation for ongoing compliance.

For many medical-device manufacturers, ISO 13485 is an important component of their quality framework. However, certification alone should not be viewed as evidence that every regulatory obligation has been addressed.

The QMS should support processes such as:

• Document control
• Design and development controls
• Supplier management
• Risk management
• Complaint handling
• CAPA
• Change control
• Production controls
• Post-market surveillance
• Training
• Record management

Companies entering Poland can therefore evaluate whether their existing QMS is sufficiently aligned with their EU medical-device strategy.

A structured Quality Management System Services approach can be particularly relevant when organizations need to connect quality processes with regulatory and market-entry requirements.

Why QMS Gaps Become Market-Entry Problems

A QMS weakness may initially appear operational but later become a regulatory issue.

For example, ineffective complaint handling can affect PMS. Weak supplier controls can affect device quality. Poor change-control processes can result in an overlooked regulatory assessment.

Therefore, QMS readiness should be assessed before — not after — commercial expansion.

Post-Market Surveillance and Vigilance

Post-market compliance is one of the areas that international manufacturers should incorporate into their Poland strategy from the beginning.

A functioning PMS system should provide a structured mechanism for collecting and evaluating information about device performance and safety after commercialization.

Relevant inputs may include:

• Customer complaints
• Serious incidents
• Non-serious incidents
• Trend information
• Field safety information
• Scientific literature
• Feedback from distributors
• Corrective and preventive actions
• Similar-device information

Vigilance processes should also define responsibilities, escalation pathways, reporting decisions, and communication procedures.

For organizations managing several markets, Pharmacovigilance Services in Poland may also be relevant where pharmaceutical products form part of a broader healthcare portfolio. The regulatory systems for medicines and devices remain distinct, but both require disciplined safety surveillance and lifecycle oversight.

Pharmaceutical Regulatory Considerations

Although this article focuses primarily on medical-device companies, pharmaceutical regulation is relevant for organizations with combination portfolios or plans to expand from devices into medicines.

The EU pharmaceutical framework is built around quality, safety, and efficacy, with marketing authorization required before medicinal products can generally be placed on the market.

Companies may need to assess whether a product should follow:

• A centralized procedure
• A decentralized procedure
• A mutual-recognition procedure
• A national procedure

The appropriate route depends on the characteristics of the product and the intended geographic scope.

The EU pharmaceutical environment is also evolving. The European Commission has reported political agreement in December 2025 to modernize the EU pharmaceutical framework, with objectives including improving access, reducing administrative burden, strengthening innovation, and addressing medicine shortages.

This illustrates why regulatory strategies should be designed as living systems rather than static launch documents.

Common Regulatory Mistakes When Entering Poland

Medical device manufacturers entering Regulatory Affairs Services in Poland can encounter several avoidable challenges.

Treating CE Marking as the Entire Strategy

CE marking is fundamental, but market entry also involves economic operators, documentation, PMS, vigilance, labeling, distribution, and lifecycle compliance.

Starting Regulatory Work Too Late

If classification, clinical evidence, QMS, or conformity assessment issues are discovered immediately before launch, timelines can become difficult to manage.

Ignoring Post-Market Requirements

PMS and vigilance should be designed before commercialization rather than added after the product is launched.

Using One Regulatory Strategy for Every EU Market

EU legislation creates harmonization, but companies still need to understand country-specific operational and implementation requirements.

Failing to Monitor Regulatory Changes

Requirements and guidance evolve. The European Commission’s medical-device pages, for example, continue to publish updates relating to standards, notified bodies, and implementation.

How Regulatory Intelligence Supports Market Entry

Regulatory intelligence can help companies identify changes before they affect product plans.

A useful regulatory-intelligence process tracks:

• New legislation
• Regulatory guidance
• Competent-authority communications
• Harmonized standards
• Notified-body developments
• Safety communications
• Changes affecting product classification
• Submission requirements
• Post-market expectations

For multinational companies, dedicated ories.

The objective is not simply to collect regulatory news. Effective intelligence should answer:

What changed? Why does it matter? Which products are affected? What action should the company take?

Building a Practical Poland Regulatory Strategy

A practical strategy can be organized into six stages:

Stage 1: Product Assessment

Identify the product type, intended purpose, classification, target users, and applicable legislation.

Stage 2: Regulatory Gap Assessment

Compare the current regulatory package against EU and Poland market-entry requirements.

Stage 3: Compliance Planning

Define requirements for conformity assessment, technical documentation, QMS, clinical evidence, labeling, economic operators, and registration activities.

Stage 4: Market-Entry Execution

Coordinate regulatory submissions, registrations, translations, commercial readiness, distribution arrangements, and required documentation.

Stage 5: PMS and Vigilance

Establish complaint, PMS, vigilance, corrective-action, and safety-monitoring processes before launch.

Stage 6: Lifecycle Management

Regulatory compliance continues after launch. Changes to products, labeling, manufacturing, suppliers, clinical evidence, or intended use may trigger regulatory assessments.

This lifecycle perspective is particularly important for companies managing multiple products and markets. A structured Regulatory Affairs Lifecycle Management tool approach can help organizations connect regulatory decisions across development, registration, commercialization, and post-market activities.

Conclusion

Poland can be an important market for medical device manufacturers seeking to expand within the EU, but successful entry requires more than obtaining the necessary product documentation.

Companies should evaluate classification, conformity assessment, technical documentation, economic-operator responsibilities, language requirements, QMS readiness, PMS, vigilance, and lifecycle management as interconnected parts of one regulatory strategy.

For pharmaceutical companies, the regulatory pathway is different and may involve national or European authorization procedures depending on the product and intended markets.